MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) today announced that its financial guidance for the full-year 2007 is presently under review due to the ongoing evaluation of all financial implications related to the newly signed collaboration agreement with Novartis.  In conjunction with the successful execution of the Novartis agreement, MorphoSys expects to incur one-off advisory expenses of up to EUR 6 million, which will be paid in 2007.  Furthermore, in accordance with the new Novartis agreement, MorphoSys has decided not to extend its ongoing collaborations with Bayer-Schering and Centocor, which are due to expire in December 2007.  The current active therapeutic antibody development programs with these two partners will nonetheless continue.  The impact of the aforementioned and other related effects on revenues and expenses has not been considered in the financial guidance given to date for the year 2007.

 

MorphoSys will publish an update once the financial guidance review is concluded.

MorphoSys will hold a public conference call and live audio webcast on December 3, 2007 at 10:00 CET to provide detailed information on its new strategic alliance with Novartis.

Dial-in number for the Conference Call:  +49 (0)69 9897 2623 (listen-only)
UK residents: +44 (0)20 7138 0844
Confirmation code: 8460477

Please dial in 10 minutes before the beginning of the conference.

MorphoSys AG offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com

An audio replay and manuscripts of the conference will be available following the live event on http://www.morphosys.com/conferencecalls

 

For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Public Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com